Engagement type
Transformation
Case study
Global Biotech CQV Acceleration
A late-stage biotech needed to bring two production suites online in under nine months without increasing compliance risk.
BiopharmaTop-20 oncology biotechAnonymized Engagement
Primary lens
Quality + Compliance
Delivery model
Hybrid Pod
Executive summary
Business context and decision pressure
This engagement focused on restoring delivery confidence under strict regulatory and operational constraints. The client needed measurable progress quickly, but without compromising documentation quality, audit defensibility, or cross-functional alignment.
BEPC aligned quality, operations, and leadership around one execution model so critical decisions moved faster, closure quality improved, and milestone risk became visible early.
Objectives
- Stabilize biopharma execution with clear governance ownership.
- Reduce cycle-time friction without sacrificing closure quality or evidence standards.
- Increase executive visibility so risk can be escalated and resolved earlier.
Execution
Approach
- Set up a joint BEPC-client governance pod with daily execution standups
- Implemented a risk-tiered protocol strategy across direct and indirect impact systems
- Built traceability automation for faster protocol review and approval
Impact
Results
- Suites released 11 weeks ahead of revised baseline
- Protocol cycle times reduced by 38%
- No critical findings during mock inspection
Timeline model
How the work was sequenced
Phase 1
Baseline and risk framing
Mapped the current-state constraints for top-20 oncology biotech and aligned the high-risk workstreams to one decision model.
Phase 2
Cross-functional execution sprint
Implemented a shared cadence across quality, operations, and leadership with explicit accountability checkpoints.
Phase 3
Control hardening and sustainment
Standardized documentation patterns, closure criteria, and escalation triggers to sustain gains beyond initial milestones.
Business impact
What changed for the client
- Suites released 11 weeks ahead of revised baseline
- Protocol cycle times reduced by 38%
- No critical findings during mock inspection
- Leadership gained clearer line-of-sight on blockers, ownership, and next critical decisions.
- Program velocity improved while maintaining audit-defensible evidence quality.
Replication guide
How to apply this model
- Start with a focused governance baseline tied to the same risk profile shown in this biopharma case.
- Define one evidence standard and one closure definition across all contributors.
- Use weekly execution reviews and monthly executive checkpoints to keep momentum and control aligned.
- Scale only after cycle-time and closure quality move in the same direction.